Demuth to lead R&D at MorphoSys as Peters retires

MorphoSys AG (NASDAQ:MOR; Xetra:MOR) hired Tim Demuth as chief R&D officer and member of the executive committee, succeeding Malte Peters who will retire at year-end. Demuth will join MorphoSys on Oct. 1 from Pieris Pharmaceuticals Inc. (NASDAQ:PIRS), where he is CMO. Peters’ accomplishments at MorphoSys include the accelerated approval of Monjuvi tafasitamab-cxix in the U.S. and EU; the successful integration of Constellation Pharmaceuticals Inc., which MorphoSys acquired in 2021; and the optimization of the Phase III study of pelabresib in first-line myelofibrosis.

Revolution Medicines Inc. (NASDAQ:RVMD) promoted Jack Anders to CFO and Jeff Cislini to SVP, general counsel; and hired Daniel Simon as CBO. Anderson was most recently SVP, finance and principal financial and accounting officer, and Cislini was VP, deputy general counsel and corporate secretary at the company. Simon joins from Guardant Health Inc. (NASDAQ:GH), where he was SVP, biopharma business development. Revolution is developing inhibitors to suppress diverse oncogenic variants of RAS proteins...